Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
Kelun Biotech (1885133D CH)
Watchlist
39
Analysis
Health Care
•
China
Kelun Biotech operates biotechnology businesses. The Company develops and provides biological drugs, chemical raw materials, chemical preparations, and other products. Kelun Biotech also operates import and export businesses.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
LG Energy Solution
•
16 Jul 2023 08:08
ECM Weekly (16th July 2023) - LG Energy, Socionext, Plus Alpha, Syngenta, Cinema XXI, Genda, Fadu
Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.
Sumeet Singh
Follow
712 Views
Share
bullish
•
Kelun Biotech
•
12 Jul 2023 09:25
Pre-IPO Kelun Biotech (PHIP Updates) - Some Points Worth the Attention
Currently, Kelun-Biotech's market value has already been higher than that of Keymed. Considering Keymed has complete R&D team within the company,...
Xinyao (Criss) Wang
Follow
859 Views
Share
bullish
•
Kelun Biotech
•
10 Jul 2023 15:03
Kelun-Biotech (科伦博泰) IPO Trading: Lukewarm Demand but Peers Have Done Well Recently
Kelun Biotech will start trading on July 11th. We provide an update of the IPO before its debut. We think the deal attracted lukewarm demand but...
Ke Yan, CFA, FRM
Follow
566 Views
Share
bullish
•
Singapore Airlines
•
02 Jul 2023 07:18
ECM Weekly (2nd July 2023) - Tryt, J&T Express, Redox, Kelun, 4Paradigm, SIA, M&A Research, Walsin
Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.
Sumeet Singh
Follow
606 Views
Share
bearish
•
Kelun Biotech
•
28 Jun 2023 17:29
Kelun-Biotech (科伦博泰) IPO: Fairly Valued at Best
Kelun-biotech, a China-based biopharmaceutical company, launched a deal to raise up to US$200m via a Hong Kong listing. We provide quick thoughts...
Ke Yan, CFA, FRM
Follow
742 Views
Share
First
Previous
4
5
6
7
8
Next
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4
x